PKI-402 is primarily used in cancer research and treatment due to its ability to inhibit specific kinases involved in tumor growth. It targets PI3K and mTOR signaling pathways, which are often dysregulated in various cancers, making it a potential therapeutic agent for malignancies such as breast, lung, and prostate cancer. In preclinical studies, PKI-402 has shown promise in reducing tumor proliferation and inducing apoptosis in cancer cells. Its application extends to combination therapies, where it is tested alongside other anticancer drugs to enhance efficacy and overcome drug resistance. Researchers also explore its potential in personalized medicine, tailoring treatments based on the genetic profile of the tumor.